| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 36 | 2025 | 3021 | 2.650 |
Why?
|
| Genetic Predisposition to Disease | 28 | 2025 | 2356 | 1.900 |
Why?
|
| Germ-Line Mutation | 14 | 2025 | 346 | 1.630 |
Why?
|
| Genetic Testing | 16 | 2024 | 539 | 1.080 |
Why?
|
| Biomarkers, Tumor | 12 | 2021 | 1541 | 0.950 |
Why?
|
| BRCA2 Protein | 10 | 2024 | 161 | 0.920 |
Why?
|
| Elasticity Imaging Techniques | 5 | 2021 | 56 | 0.880 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2024 | 102 | 0.800 |
Why?
|
| Hospital Mortality | 1 | 2024 | 399 | 0.780 |
Why?
|
| Critical Care | 1 | 2024 | 384 | 0.740 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 2327 | 0.670 |
Why?
|
| BRCA1 Protein | 8 | 2023 | 204 | 0.670 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2019 | 163 | 0.670 |
Why?
|
| Ovarian Neoplasms | 7 | 2023 | 768 | 0.650 |
Why?
|
| Female | 69 | 2025 | 46401 | 0.650 |
Why?
|
| Drugs, Investigational | 2 | 2016 | 38 | 0.640 |
Why?
|
| Humans | 97 | 2025 | 89613 | 0.630 |
Why?
|
| Aged | 40 | 2025 | 19158 | 0.620 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 357 | 0.610 |
Why?
|
| Prognosis | 10 | 2024 | 3785 | 0.600 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2016 | 112 | 0.590 |
Why?
|
| Stroke | 2 | 2023 | 990 | 0.550 |
Why?
|
| Middle Aged | 44 | 2025 | 26012 | 0.540 |
Why?
|
| Neoplasms | 11 | 2023 | 3054 | 0.520 |
Why?
|
| Checkpoint Kinase 2 | 5 | 2023 | 26 | 0.500 |
Why?
|
| Genes, BRCA2 | 5 | 2023 | 161 | 0.490 |
Why?
|
| Drug Screening Assays, Antitumor | 5 | 2018 | 78 | 0.470 |
Why?
|
| Adult | 38 | 2025 | 26704 | 0.450 |
Why?
|
| Ultrasonography, Mammary | 4 | 2022 | 83 | 0.440 |
Why?
|
| Osteoporotic Fractures | 2 | 2024 | 50 | 0.430 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2025 | 160 | 0.420 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2017 | 488 | 0.420 |
Why?
|
| Case-Control Studies | 14 | 2021 | 1862 | 0.420 |
Why?
|
| Thrombectomy | 3 | 2024 | 189 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2019 | 1281 | 0.400 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 1446 | 0.390 |
Why?
|
| Aged, 80 and over | 18 | 2024 | 6771 | 0.390 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 5 | 2023 | 14 | 0.380 |
Why?
|
| Recombinational DNA Repair | 2 | 2021 | 9 | 0.370 |
Why?
|
| Microbiota | 4 | 2021 | 406 | 0.350 |
Why?
|
| Models, Statistical | 3 | 2024 | 575 | 0.340 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 2364 | 0.330 |
Why?
|
| Genetic Variation | 6 | 2022 | 1380 | 0.330 |
Why?
|
| Prospective Studies | 13 | 2024 | 4309 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 3 | 2020 | 682 | 0.330 |
Why?
|
| Risk Assessment | 6 | 2024 | 2304 | 0.310 |
Why?
|
| Machine Learning | 2 | 2024 | 263 | 0.310 |
Why?
|
| Mutation | 13 | 2021 | 4160 | 0.310 |
Why?
|
| Thrombosis | 2 | 2021 | 301 | 0.300 |
Why?
|
| Skin | 3 | 2018 | 589 | 0.300 |
Why?
|
| Multifactorial Inheritance | 2 | 2019 | 173 | 0.280 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 4 | 2023 | 57 | 0.280 |
Why?
|
| DNA-Binding Proteins | 4 | 2023 | 1244 | 0.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 1125 | 0.280 |
Why?
|
| Sulfonylurea Compounds | 2 | 2024 | 65 | 0.280 |
Why?
|
| Cell Line, Tumor | 9 | 2023 | 2582 | 0.280 |
Why?
|
| Treatment Outcome | 12 | 2024 | 8218 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 194 | 0.260 |
Why?
|
| Receptor, ErbB-2 | 2 | 2019 | 247 | 0.260 |
Why?
|
| Biomarkers | 5 | 2024 | 1768 | 0.250 |
Why?
|
| Pyridones | 2 | 2023 | 56 | 0.250 |
Why?
|
| Male | 29 | 2024 | 42488 | 0.250 |
Why?
|
| Young Adult | 14 | 2021 | 6368 | 0.250 |
Why?
|
| Precision Medicine | 3 | 2020 | 409 | 0.250 |
Why?
|
| HIV-1 | 3 | 2019 | 167 | 0.250 |
Why?
|
| Genes, BRCA1 | 3 | 2021 | 192 | 0.250 |
Why?
|
| Follow-Up Studies | 6 | 2024 | 3659 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1180 | 0.240 |
Why?
|
| Registries | 4 | 2024 | 791 | 0.240 |
Why?
|
| Risk Factors | 11 | 2024 | 5517 | 0.240 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 9 | 0.230 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 36 | 0.230 |
Why?
|
| HIV Infections | 3 | 2019 | 846 | 0.230 |
Why?
|
| Predictive Value of Tests | 4 | 2024 | 1727 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 2 | 2024 | 375 | 0.230 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2025 | 117 | 0.230 |
Why?
|
| Electromyography | 1 | 2024 | 195 | 0.220 |
Why?
|
| Electronic Health Records | 2 | 2024 | 351 | 0.220 |
Why?
|
| Machado-Joseph Disease | 1 | 2023 | 8 | 0.220 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 351 | 0.220 |
Why?
|
| Erythrocytes | 2 | 2021 | 254 | 0.220 |
Why?
|
| Rivaroxaban | 1 | 2023 | 12 | 0.220 |
Why?
|
| Hip Fractures | 1 | 2023 | 46 | 0.220 |
Why?
|
| Receptors, Estrogen | 3 | 2021 | 394 | 0.220 |
Why?
|
| Reproducibility of Results | 8 | 2023 | 2763 | 0.210 |
Why?
|
| Dabigatran | 1 | 2023 | 25 | 0.210 |
Why?
|
| Diabetic Retinopathy | 1 | 2024 | 91 | 0.210 |
Why?
|
| DNA Repair Enzymes | 2 | 2020 | 55 | 0.210 |
Why?
|
| Biosensing Techniques | 1 | 2023 | 73 | 0.210 |
Why?
|
| Genetic Association Studies | 3 | 2020 | 294 | 0.210 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2024 | 187 | 0.210 |
Why?
|
| Breast Density | 2 | 2019 | 36 | 0.200 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2021 | 2411 | 0.200 |
Why?
|
| Warfarin | 1 | 2023 | 104 | 0.200 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2023 | 76 | 0.200 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 538 | 0.200 |
Why?
|
| Cohort Studies | 8 | 2021 | 2878 | 0.200 |
Why?
|
| Skilled Nursing Facilities | 1 | 2022 | 41 | 0.200 |
Why?
|
| Alcoholism | 1 | 2023 | 180 | 0.200 |
Why?
|
| Fractals | 1 | 2021 | 42 | 0.200 |
Why?
|
| Genome-Wide Association Study | 4 | 2021 | 1686 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2024 | 477 | 0.200 |
Why?
|
| Leuprolide | 1 | 2021 | 35 | 0.190 |
Why?
|
| Research Design | 2 | 2023 | 589 | 0.190 |
Why?
|
| Apraxias | 1 | 2021 | 3 | 0.190 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2018 | 71 | 0.190 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2021 | 9 | 0.190 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 497 | 0.190 |
Why?
|
| Abdominal Fat | 1 | 2021 | 13 | 0.190 |
Why?
|
| Administration, Oral | 1 | 2023 | 666 | 0.190 |
Why?
|
| Mammography | 2 | 2022 | 474 | 0.190 |
Why?
|
| Metformin | 1 | 2022 | 124 | 0.180 |
Why?
|
| Carcinoma, Lobular | 1 | 2021 | 81 | 0.180 |
Why?
|
| MicroRNAs | 2 | 2016 | 555 | 0.180 |
Why?
|
| Elasticity | 1 | 2021 | 97 | 0.180 |
Why?
|
| Speech | 1 | 2021 | 85 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 145 | 0.180 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 19 | 0.180 |
Why?
|
| Oligopeptides | 1 | 2021 | 188 | 0.180 |
Why?
|
| Clinical Decision-Making | 2 | 2024 | 280 | 0.180 |
Why?
|
| Patient Positioning | 1 | 2021 | 65 | 0.180 |
Why?
|
| Neuroimaging | 1 | 2021 | 116 | 0.180 |
Why?
|
| Mutation, Missense | 4 | 2024 | 280 | 0.180 |
Why?
|
| Thromboembolism | 1 | 2021 | 119 | 0.170 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 375 | 0.170 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2019 | 3 | 0.170 |
Why?
|
| Tomography, Optical Coherence | 1 | 2020 | 136 | 0.170 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2019 | 25 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2021 | 72 | 0.170 |
Why?
|
| Anticoagulants | 1 | 2023 | 428 | 0.170 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2016 | 25 | 0.170 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2016 | 44 | 0.170 |
Why?
|
| Viremia | 1 | 2019 | 49 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 447 | 0.170 |
Why?
|
| Quality Control | 2 | 2017 | 117 | 0.160 |
Why?
|
| Patient Discharge | 1 | 2022 | 323 | 0.160 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 35 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2021 | 353 | 0.160 |
Why?
|
| Urinary Bladder | 1 | 2021 | 248 | 0.160 |
Why?
|
| Trastuzumab | 1 | 2019 | 73 | 0.160 |
Why?
|
| Plasmids | 2 | 2016 | 291 | 0.160 |
Why?
|
| Caspase 8 | 1 | 2018 | 34 | 0.160 |
Why?
|
| HIV Protease | 1 | 2018 | 10 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2022 | 2016 | 0.160 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 397 | 0.150 |
Why?
|
| Emollients | 1 | 2018 | 3 | 0.150 |
Why?
|
| Anti-HIV Agents | 2 | 2013 | 159 | 0.150 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 1172 | 0.150 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 175 | 0.150 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2018 | 105 | 0.150 |
Why?
|
| Macrophages | 1 | 2021 | 578 | 0.150 |
Why?
|
| NADPH Oxidase 1 | 1 | 2017 | 2 | 0.150 |
Why?
|
| Patient Admission | 1 | 2018 | 114 | 0.140 |
Why?
|
| Interleukin-13 | 1 | 2017 | 38 | 0.140 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2017 | 11 | 0.140 |
Why?
|
| Hospitals | 1 | 2020 | 303 | 0.140 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2017 | 16 | 0.140 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 188 | 0.140 |
Why?
|
| Valine | 1 | 2017 | 62 | 0.140 |
Why?
|
| Cell Cycle Proteins | 2 | 2017 | 399 | 0.140 |
Why?
|
| Family | 1 | 2019 | 325 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 120 | 0.140 |
Why?
|
| Interleukin-4 | 1 | 2017 | 129 | 0.140 |
Why?
|
| Disease Progression | 1 | 2021 | 1463 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 2 | 2016 | 302 | 0.140 |
Why?
|
| Malassezia | 1 | 2016 | 2 | 0.140 |
Why?
|
| Drug Therapy | 1 | 2017 | 69 | 0.140 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 65 | 0.140 |
Why?
|
| Dermatomycoses | 1 | 2016 | 9 | 0.140 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2017 | 95 | 0.140 |
Why?
|
| Algorithms | 4 | 2019 | 1903 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 3 | 0.140 |
Why?
|
| Brain Ischemia | 1 | 2021 | 401 | 0.140 |
Why?
|
| Nitrophenols | 1 | 2016 | 11 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2016 | 20 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 172 | 0.130 |
Why?
|
| Puberty | 1 | 2016 | 60 | 0.130 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 21 | 0.130 |
Why?
|
| Artificial Intelligence | 2 | 2011 | 328 | 0.130 |
Why?
|
| Biphenyl Compounds | 1 | 2016 | 59 | 0.130 |
Why?
|
| Gene Expression | 2 | 2021 | 1309 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 795 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2024 | 9127 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2020 | 552 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 208 | 0.130 |
Why?
|
| Reference Standards | 1 | 2016 | 144 | 0.130 |
Why?
|
| Phosphotransferases | 1 | 2015 | 65 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 412 | 0.130 |
Why?
|
| Isoindoles | 1 | 2015 | 14 | 0.130 |
Why?
|
| Medical History Taking | 3 | 2021 | 82 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 289 | 0.130 |
Why?
|
| Breast | 3 | 2022 | 292 | 0.130 |
Why?
|
| Inflammation | 1 | 2021 | 975 | 0.130 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 100 | 0.120 |
Why?
|
| Genotype | 4 | 2021 | 1853 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 47 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 268 | 0.120 |
Why?
|
| Histones | 1 | 2017 | 333 | 0.120 |
Why?
|
| Epidemiologic Research Design | 1 | 2014 | 22 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 585 | 0.120 |
Why?
|
| Obesity | 1 | 2021 | 971 | 0.120 |
Why?
|
| Piperazines | 1 | 2016 | 282 | 0.120 |
Why?
|
| Benzamides | 1 | 2015 | 234 | 0.120 |
Why?
|
| Biological Specimen Banks | 1 | 2014 | 67 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 217 | 0.110 |
Why?
|
| Paclitaxel | 1 | 2016 | 475 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2016 | 318 | 0.110 |
Why?
|
| United States | 6 | 2024 | 7050 | 0.110 |
Why?
|
| Sarcoma | 1 | 2015 | 219 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2018 | 693 | 0.110 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2013 | 3 | 0.110 |
Why?
|
| Odds Ratio | 3 | 2021 | 682 | 0.110 |
Why?
|
| Signal Transduction | 4 | 2018 | 3397 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 1185 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 1132 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 152 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 727 | 0.100 |
Why?
|
| Body Mass Index | 3 | 2021 | 774 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 571 | 0.100 |
Why?
|
| Exome | 1 | 2013 | 131 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 836 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 665 | 0.100 |
Why?
|
| Diagnosis, Differential | 3 | 2022 | 1605 | 0.100 |
Why?
|
| Adolescent | 6 | 2021 | 9305 | 0.100 |
Why?
|
| Heterozygote | 2 | 2023 | 373 | 0.100 |
Why?
|
| Erythropoietin | 1 | 2012 | 90 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 2503 | 0.100 |
Why?
|
| Quinazolines | 1 | 2013 | 212 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2013 | 140 | 0.100 |
Why?
|
| Microvessels | 2 | 2022 | 69 | 0.100 |
Why?
|
| Apoptosis | 1 | 2018 | 1717 | 0.100 |
Why?
|
| Dermatitis, Atopic | 1 | 2012 | 55 | 0.090 |
Why?
|
| Probability | 1 | 2012 | 350 | 0.090 |
Why?
|
| Metagenome | 1 | 2012 | 105 | 0.090 |
Why?
|
| Logistic Models | 3 | 2021 | 1214 | 0.090 |
Why?
|
| Body Weight | 1 | 2012 | 453 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 3 | 2021 | 868 | 0.090 |
Why?
|
| ROC Curve | 2 | 2024 | 776 | 0.090 |
Why?
|
| Oxygen Consumption | 2 | 2021 | 245 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 1734 | 0.090 |
Why?
|
| Models, Biological | 2 | 2019 | 1762 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2020 | 336 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2024 | 837 | 0.080 |
Why?
|
| Muscle, Skeletal | 2 | 2024 | 469 | 0.080 |
Why?
|
| Computer Simulation | 3 | 2020 | 1101 | 0.080 |
Why?
|
| Age of Onset | 2 | 2021 | 314 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 571 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2018 | 1498 | 0.080 |
Why?
|
| DNA, Neoplasm | 2 | 2021 | 266 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 1076 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2023 | 848 | 0.080 |
Why?
|
| Risk | 2 | 2021 | 655 | 0.080 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 2 | 2017 | 8 | 0.070 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2017 | 33 | 0.070 |
Why?
|
| RNA Helicases | 2 | 2017 | 35 | 0.070 |
Why?
|
| Virus Replication | 2 | 2019 | 326 | 0.070 |
Why?
|
| Cell Movement | 1 | 2011 | 785 | 0.070 |
Why?
|
| Internet | 2 | 2020 | 321 | 0.070 |
Why?
|
| Drug Resistance, Viral | 1 | 2007 | 48 | 0.070 |
Why?
|
| Genomics | 3 | 2017 | 775 | 0.070 |
Why?
|
| Melanoma | 1 | 2011 | 468 | 0.070 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 419 | 0.070 |
Why?
|
| Decision Making | 1 | 2012 | 669 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2021 | 457 | 0.070 |
Why?
|
| Alleles | 2 | 2021 | 1137 | 0.070 |
Why?
|
| Workflow | 2 | 2017 | 81 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2021 | 870 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 1798 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2024 | 48 | 0.060 |
Why?
|
| Databases, Genetic | 2 | 2018 | 269 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 166 | 0.060 |
Why?
|
| Learning | 1 | 2007 | 285 | 0.060 |
Why?
|
| Germ Cells | 1 | 2024 | 130 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1928 | 0.050 |
Why?
|
| Computational Biology | 2 | 2017 | 550 | 0.050 |
Why?
|
| Sitagliptin Phosphate | 1 | 2022 | 2 | 0.050 |
Why?
|
| Liraglutide | 1 | 2022 | 4 | 0.050 |
Why?
|
| Insulin Glargine | 1 | 2022 | 9 | 0.050 |
Why?
|
| Age Factors | 2 | 2018 | 1877 | 0.050 |
Why?
|
| Motor Neurons | 1 | 2024 | 176 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 885 | 0.050 |
Why?
|
| Survival Rate | 2 | 2020 | 1887 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2023 | 316 | 0.050 |
Why?
|
| Bone Density | 1 | 2023 | 211 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 18 | 0.050 |
Why?
|
| Neurobiology | 1 | 2021 | 10 | 0.050 |
Why?
|
| Cerebellum | 1 | 2023 | 249 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2021 | 76 | 0.050 |
Why?
|
| Mitochondria, Muscle | 1 | 2021 | 27 | 0.050 |
Why?
|
| Anisotropy | 1 | 2021 | 63 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2021 | 34 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2021 | 50 | 0.050 |
Why?
|
| Supine Position | 1 | 2021 | 30 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 252 | 0.050 |
Why?
|
| Everolimus | 1 | 2021 | 35 | 0.050 |
Why?
|
| Cell Count | 1 | 2021 | 199 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2021 | 71 | 0.050 |
Why?
|
| tau Proteins | 1 | 2021 | 76 | 0.050 |
Why?
|
| Fibrin | 1 | 2021 | 86 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2023 | 273 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2021 | 38 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 67 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 782 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 142 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2017 | 1668 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 191 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2021 | 226 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2021 | 107 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 413 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2021 | 150 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 312 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 68 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 107 | 0.040 |
Why?
|
| Reference Values | 1 | 2020 | 661 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2021 | 477 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2015 | 2021 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 249 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 171 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 337 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2020 | 187 | 0.040 |
Why?
|
| Child | 3 | 2016 | 7216 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 78 | 0.040 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 47 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2021 | 714 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 102 | 0.040 |
Why?
|
| Comamonadaceae | 1 | 2018 | 2 | 0.040 |
Why?
|
| Proteobacteria | 1 | 2018 | 6 | 0.040 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 153 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2668 | 0.040 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2018 | 57 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 88 | 0.040 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2018 | 20 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2022 | 353 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 205 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2018 | 77 | 0.040 |
Why?
|
| Smokers | 1 | 2018 | 46 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2020 | 453 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 1310 | 0.040 |
Why?
|
| Exercise | 1 | 2021 | 326 | 0.040 |
Why?
|
| Mice | 3 | 2019 | 11832 | 0.040 |
Why?
|
| MRE11 Homologue Protein | 1 | 2017 | 2 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 2017 | 8 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 11 | 0.040 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2017 | 13 | 0.040 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2017 | 24 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2017 | 35 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2018 | 211 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 699 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 777 | 0.040 |
Why?
|
| Mass Screening | 1 | 2022 | 645 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 1247 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 806 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 58 | 0.040 |
Why?
|
| Retreatment | 1 | 2017 | 107 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2017 | 41 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 105 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2018 | 95 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 614 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2017 | 66 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1710 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 1064 | 0.030 |
Why?
|
| Sebaceous Glands | 1 | 2016 | 28 | 0.030 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2016 | 11 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 687 | 0.030 |
Why?
|
| Aging | 1 | 2021 | 724 | 0.030 |
Why?
|
| Biodiversity | 1 | 2018 | 208 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3465 | 0.030 |
Why?
|
| Software | 1 | 2020 | 667 | 0.030 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2015 | 21 | 0.030 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2018 | 304 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2015 | 15 | 0.030 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2015 | 24 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 64 | 0.030 |
Why?
|
| Aurora Kinases | 1 | 2015 | 17 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 146 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 42 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2015 | 51 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 193 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2015 | 33 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 484 | 0.030 |
Why?
|
| Glycosylation | 1 | 2015 | 128 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 224 | 0.030 |
Why?
|
| beta Catenin | 1 | 2017 | 266 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2015 | 77 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 126 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 107 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 282 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1254 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 123 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 115 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 263 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 370 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 490 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 391 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 743 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2015 | 183 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 185 | 0.030 |
Why?
|
| Bacteria | 1 | 2018 | 481 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 740 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 334 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 865 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 279 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 524 | 0.030 |
Why?
|
| Anorexia | 1 | 2013 | 28 | 0.030 |
Why?
|
| Drug Costs | 1 | 2013 | 63 | 0.030 |
Why?
|
| Neurons | 1 | 2021 | 1588 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 27481 | 0.030 |
Why?
|
| Staphylococcus | 1 | 2012 | 24 | 0.030 |
Why?
|
| Diarrhea | 1 | 2013 | 178 | 0.020 |
Why?
|
| Molecular Typing | 1 | 2012 | 17 | 0.020 |
Why?
|
| Patient Selection | 1 | 2015 | 677 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 2329 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2013 | 236 | 0.020 |
Why?
|
| RNA, Bacterial | 1 | 2012 | 111 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 305 | 0.020 |
Why?
|
| Infant | 1 | 2018 | 3176 | 0.020 |
Why?
|
| S Phase | 1 | 2011 | 63 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 250 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 984 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 2449 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 309 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 2003 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2011 | 100 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 247 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2012 | 240 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2011 | 253 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 437 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2012 | 337 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 816 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 271 | 0.020 |
Why?
|
| Hypertension | 1 | 2013 | 747 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 5337 | 0.020 |
Why?
|
| Quality of Life | 1 | 2014 | 1673 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 3756 | 0.010 |
Why?
|